Safety and Efficacy of Vibegron in Men With Overactive Bladder Symptoms on Pharmacotherapy for Benign Prostatic Hyperplasia: Results From the 28-Week Open-Label COURAGE Extension Trial Completing the 52-Week Phase 3 Evaluation
Abstract
In the 24-week, phase 3 COURAGE trial, vibegron was associated with significant improvements vs placebo in all primary and key secondary efficacy end points and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH). Safety and efficacy of vibegron were evaluated in a 28-week open-label extension study.
Participants who completed COURAGE received once-daily vibegron 75 mg for 28 additional weeks in the extension study. The primary outcome was safety (adverse events [AEs], clinical laboratory assessments, vital signs, postvoid residual urine volume [PVR], and International Prostate Symptom Score [IPSS]-total score). Secondary outcomes were change from baseline to week 52 in mean daily micturitions, urgency episodes, nocturia episodes, urge urinary incontinence episodes, IPSS-storage score, and volume voided per micturition. Exploratory outcomes included change from baseline to week 52 in the OAB-questionnaire and Patient Global Impression scales.
Overall, 276 participants enrolled (vibegron, n = 142 [52-week cohort]; placebo, n = 134 [28-week cohort]); 90.6% completed the extension, with 9 participants discontinuing vibegron because of AEs. In the 52-week cohort, AE incidences were similar to double-blind treatment; there were no clinically relevant changes in laboratory parameters, vital signs or PVR, and median IPSS-total score decreased from baseline to week 52. Improvements in all secondary and exploratory…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 276 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.